ESTUDIO FASE II, MULTICÉNTRICO, ABIERTO, ALEATORIZADO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE DOS POSOLOGÍAS DISTINTAS DE LDE225 ORAL, EN PACIENTES ADULTOS CON LEUCEMIA AGUDA REFRACTARIA/EN RECIDIVA O EN PACIENTES CON EDAD AVANZADA SIN TRATAMIENTO PREVIO.

Poveda-Andrés JL, Bosó-Ribelles V

Article. 10.1016/j.thromres.2018.12.027. 2019

Biallelic TET2 mutation sensitizes to 5'-azacitidine in acute myeloid leukemia.

Stölzel F; (...); Allan, James M.

Article. 10.1172/jci.insight.150368. 2022

Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022

Biology and management of therapy-related acute promyelocytic leukemia.

Lo-Coco F; (...); Sanz MA

Article. 10.1097/CCO.0000000000000013. 2013

Biosimilares: viejas polemicas con nuevos argumentos.

Editorial Material. 10.7399/fh.2015.39.3.8978. 2015

BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population

Perez-Huertas, P; (...); Poveda-Andres, JL

Article. 10.1177/1043454216631952. 2017

Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Platzbecker, Uwe; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2022-160127. 2022

BLINATUMOMAB IMPROVED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY (TOWER)

Topp, M. S.; (...); Kantarjian, H.

Meeting Abstract. 2016

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Kantarjian, H; (...); Topp, MS

Article. 10.1056/NEJMoa1609783. 2017

Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen

Sanz J; (...); Sanz GF

Article. 10.1016/j.bbmt.2014.12.038. 2015

Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

Blanes M; (...); de la Rubia J

Article. 10.3109/10428194.2014.922182. 2015

Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience

Garcia-Robles, AA; (...); Fernandez-Navarro, JM

Meeting Abstract. 2017

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2022-158030. 2022

Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience

Gayoso, J; (...); Diez-Martin, JL

Article. 10.1038/bmt.2016.115. 2016

Calidad y Legibilidad de la Hoja de Informacion al Paciente en Estudios con Analisis Farmacogenetico.

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 2015

Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2020.12.019. 2021

CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

Barragán E; (...); Odero MD

Letter. 10.3324/haematol.2014.118117. 2015

Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia

Morote-Faubel, Mireya; (...); Cervera, Jose

Meeting Abstract. 10.1182/blood-2023-177571. 2023

CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA

Garcia, ML; (...); Gonzalez, EB

Meeting Abstract. 2017

Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Heuser, M; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.116. 2019

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (vol 100, pg 1181, 2021)

Heuser, Michael; (...); Cortes, Jorge E.

Article. 10.1007/s00277-021-04545-5. 2021

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.

Heuser M; (...); Cortes JE

Article. 10.1007/s00277-021-04465-4. 2021

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Article. 10.1016/j.thromres.2021.07.009. 2021

Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group

Romero, Alejandra; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-163869. 2022

Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

Sanchez, R; (...); Martinez-Lopez, J

Article. 10.1007/s00277-017-3002-1. 2017

Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study

Pinana, JL; (...); Navarro, D

Article. 10.1093/cid/ciy792. 2019

Clinical evaluation of rituximab treatment for neuromyelitis optica

Fernández-Megía MJ; (...); Poveda-Andrés JL

Article. 10.1016/j.nrl.2014.09.001. 2015

Clinical experiences with cannabinoids in spasticity management in multiple sclerosis

Lorente Fernández L; (...); Casanova-Estruch B

Article. 10.1016/j.nrl.2013.06.014. 2014

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)

Vicente, Navarro; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-190296. 2023

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

Bernal, Teresa; (...); Montesinos, Pau

Article. 10.1002/cam4.6120. 2023

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Perl, AE; (...); Tiu, RV

Meeting Abstract. 2021

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.

Perl, Alexander E.; (...); Altman, Jessica K.

Article. 10.1038/s41408-022-00677-7. 2022

Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Daver, Naval G.; (...); Kantarjian, Hagop M.

Meeting Abstract. 10.1182/blood-2019-128648. 2019

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Labrador, J; (...); GATLA Grp

Article. 10.1080/10428194.2018.1522438. 2019

Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics

Alonso, CM; (...); Barragan, E

Article. 10.1016/j.jmoldx.2018.09.009. 2019

Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study

Bassan, R; (...); Cong, Z

Article. 10.1007/s12325-019-00910-z. 2019

Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)

Colmenares, Rafael; (...); Montesinos, Pau

Meeting Abstract. 2023

Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes

Martinez-Losada, C; (...); Sanchez-Garcia, J

Letter. 10.3324/haematol.2018.188433. 2018

Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing

Ibanez, Mariam; (...); Cervera, Jose

Meeting Abstract. 10.1182/blood.V128.22.598.598. 2016

CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.

Chorão P; (...); Sanz J

Article. 10.1016/j.jtct.2024.01.082. 2024

Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation

Stiff, PJ; (...); Sanz, G

Article. 10.1016/j.bbmt.2018.02.012. 2018

Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018

Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia.

Lucena-Araujo, Antonio R.; (...); Rego, Eduardo M.

Article. 10.1182/blood.2019000239. 2019

Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.

De La Puerta R; (...); Piñana JL

Article. 10.1038/s41409-021-01319-5. 2021

Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation.

Montoro J; (...); Piñana JL

Article. 10.1038/s41409-020-0943-0. 2020

COMPARATIVE STUDY OF HEREDITARY SPHEROCYTOSIS USING FLOW CYTOMETRY AND OSMOTIC GLOBULAR FRAGILITY

Cordon Gallego, L.; (...); Sanz Alonso, M. A.

Meeting Abstract. 2015

Comparative Study of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation Versus Hematopoietic Stem Cell Transplantation

Romero, Samuel, Sr.; (...); Sanz, Miguel Angel

Article. 2015

Comparison between Two Protocols for Platelet Transfusion in Patients Undergoing ABO Incompatible Hematopoietic Stem Cell Transplantation

Carpio, N; (...); Sanz, M

Meeting Abstract. 2018

COMPARISON OF AZACITIDINE AND DECITABINE FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS

Saiz-Rodriguez, M.; (...); Labrador, J.

Meeting Abstract. 2020

COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)

Kuendgen, A.; (...); Sanz, G.

Meeting Abstract. 2021

Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia

Ribera, JM; (...); PETHEMA Grp

Article. 10.1016/j.leukres.2018.03.010. 2018

Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Meeting Abstract. 2020

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Sargas, Claudia; (...); Montesinos, Pau

Article. 10.1038/s41408-023-00835-5. 2023

Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation

Solves, P; (...); Sanz, GF

Article. 10.1111/ejh.13270. 2019

Complex Karyotype with >= 3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Genesca, Eulalia; (...); Maria Ribera, Josep

Meeting Abstract. 2020

Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.

Gil, Jose Vicente; (...); Barragan, Eva

Article. 10.3389/fmolb.2024.1362081. 2024

Consensus document for anaesthesiologist-assisted sedation in interventional cardiology procedures.

Martinez-Dolz, L; (...); Alvarez, J

Article. 10.1016/j.redare.2021.01.001. 2021

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil C; (...); Genesca E

Article. 10.3324/haematol.2024.285416. 2024

Conventional induction and post-remission therapy in APL: Have we arrived?

Sanz MA, Iacoboni G, Montesinos P

Article. 10.1016/j.beha.2014.04.004. 2014

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Boluda, Blanca; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-160136. 2022

Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome

Villalba, A; (...); Senent, L

Letter. 10.1007/s00277-018-3334-5. 2018

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups

Article. 10.1007/s00277-018-3277-x. 2018

Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.

Montesinos P; (...); Sanz MÁ

Correction. 10.1007/s00277-020-03933-7. 2020

Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352].

Rodríguez-Medina C; (...); Montesinos P

Correction. 10.1016/j.leukres.2020.106388. 2020

Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia (vol 13, 1302993, 2023)

Orgueira, Adrian Mosquera; (...); Encinas, Manuel Mateo Perez

Correction. 10.3389/fonc.2023.1302993. 2023

COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

Mareque, M; (...); Sierra, J

Article. 10.2147/CEOR.S302097. 2021

Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1080/13696998.2017.1311903. 2017

Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020

COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018

COST-EFFECTIVENESS OF GEMTUZUMAB OZOGAMICIN IN COMBINATION WITH STANDARD CHEMOTHERAPY IN FIRST-LINE TREATMENT IN PATIENTS WITH CD-33-POSITIVE ACUTE MYELOID LEUKEMIA IN SPAIN

Montesinos, P.; (...); Guinea, J. M.

Meeting Abstract. 2020

Cost-effectiveness of methoxy polyethylene glycolepoetin beta versus conventional epoetin in the treatment of anaemia secondary to chronic kidney disease in clinical practice

Lorente-Fernandez, L; (...); Poveda-Andres, JL

Article. 10.1136/ejhpharm-2013-000426. 2015

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain

Arenaza, A; (...); Vinent, JL

Article. 10.2147/CEOR.S222879. 2019

COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020

Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Lancet, Jeffrey; (...); Carraway, Hetty E.

Meeting Abstract. 10.1182/blood-2023-173149. 2023

COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)

Rosenberg, Aaron; (...); Khouri, Jack

Meeting Abstract. 2023

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Letter. 10.1111/hae.13733. 2019

Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019

Current Results on Overall Survival with oral Azacitidine Therapy in Patients with acute Myeloid Leukemia in first Remission after intensive Chemotherapy in the Phase 3 QUAZAR Study

Pfeilstoecker, M.; (...); Roboz, G. J.

Meeting Abstract. 2022

CURRENT STATE OF ACUTE MYELOID LEUKEMIA IN SPAIN: RESULTS FROM A DELPHI STUDY ON EPIDEMIOLOGY, DISEASE MANAGEMENT AND UNMET NEEDS

Montesinos, P; (...); Sierra, J

Meeting Abstract. 2018

Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs.

Montesinos P, Gil A, Sierra J

Letter. 10.1016/j.medcli.2020.04.032. 2020

Current treatment of acute promyelocytic leukemia

Sanz, MA

Meeting Abstract. 2019

Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024

Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae

Rechenberger, J; (...); Kuster, B

Article. 10.3390/proteomes7010002. 2019

Challenges in the diagnosis and treatment of secondary acute myeloid leukemia

Ossenkoppele, G, Montesinos, P

Review. 10.1016/j.critrevonc.2019.03.003. 2019

Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib plus azacitidine or placebo plus azacitidine.

Schuh, Andre C.; (...); Montesinos, Pau

Meeting Abstract. 2022

CHANGES IN THE HEMATIC AND SERUM GROUP IN PATIENTS SUBJECTED TO TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS WITH ABO MAYOR INCOMPATIBILITY

Balsera, MS; (...); Sanz, M. A.

Meeting Abstract. 2017

Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study

JUAN PALAU BARGUES; (...); Sanz MA

Article. 10.1080/10245332.2017.1311442. 2017

Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.

Cicconi, L; (...); Abla, O

Article. 10.1038/s41408-021-00561-w. 2021

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.

Sobas M; (...); PETHEMA, HOVON, PALG, GATLA cooperative groups

Article. 10.1111/ejh.13346. 2020

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Genesca, E; (...); Ribera, JM

Meeting Abstract. 10.1182/blood-2018-99-114559. 2018

Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study

Kayser, S; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-111768. 2018

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Kayser, Sabine; (...); Schlenk, Richard F.

Meeting Abstract. 10.1182/blood-2021-150281. 2021

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.

Kayser, Sabine; (...); Schlenk, Richard F.

Meeting Abstract. 10.3324/haematol.2022.281137. 2022

Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

Kayser S; (...); Levis MJ

Article. 10.3324/haematol.2021.278645. 2022

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.

Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group

Article. 10.3390/cancers14112817. 2022

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Palanques-Pastor, Tomas; (...); Montesinos, Pau

Article. 10.1080/10428194.2021.1948031. 2021

Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Stahl, M; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-112974. 2018

CHARACTERIZATION OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA BY MEANS OF IMMUNOLOGICAL AND MOLECULAR TECHNIQUES: RESULTS OF THE GEPTT NATIONAL COLLECTION

Liquori, A.; (...); Gomez-Segui, I

Meeting Abstract. 2019

CHARACTERIZATION OF MUTATIONS ALTERING THE PROCESS OF SPLICING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2018

CHARACTERIZATION OF RECURRENTLY MUTATED GENES IN ACUTE MYELOID LEUKEMIA DE NOVO WITH NORMAL KARPOTYPE BY TARGETED MASSIVE SEQUENCING

Ibanez, M.; (...); Cervera, J.

Article. 2015

CHARACTERIZATION OF THE GENOMIC AND TRANSCRIPTOMIC PROFILE OF THE ACUTE MYELOID LEUKEMIA (AML) SUBGROUP "CHROMATIN-SPLICEOSOME"

Alessandro, Liquori; (...); Zamora Jose, Cervera

Meeting Abstract. 2020

Characterization of three new HLA Class I Alleles in Spanish Caucasians, HLA-A02:620, HLA-B27:150 and HLA-B*07:05:01:02

Balas, A; (...); Vicario, JL

Article. 10.1111/iji.12317. 2017

Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.

Ribera JM; (...); Orfao A

Article. 10.1182/blood.2020007311. 2020

Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt, L; (...); Schliemann, C

Article. 10.1200/JCO.19.00416. 2019

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Gonzalez, Carmen; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-180646. 2023

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Review. 10.1080/17512433.2019.1573668. 2019

Decitabine as Salvage Therapy after Azacitidine in AML

De La Fuente, A; (...); Montesinos, P

Meeting Abstract. 2019

Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.

Montesinos, Pau, Sossa-Melo, Claudia

Article. 10.1016/S2352-3026(23)00308-3. 2023

DEEP SEQUENCING OF 23 GENES DESIGNATED BY TCGA STUDY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Ibanez, M.; (...); Cervera, J.

Meeting Abstract. 2016

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018

DESCRIPTIVE STUDY OF THE RECORD OF THROMBOTIC MICROANGIOPATHY IN A SINGLE CENTRE

Romero Dominguez, S.; (...); Sanz Alonso, M. A.

Meeting Abstract. 2015

Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Roboz GJ; (...); Kantarjian H

Article. 10.2217/fon.15.326. 2016

Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain

Lalaoui, R; (...); Rolain, JM

Article. 10.1016/j.jiac.2019.03.007. 2019

Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019

DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019

Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024

Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024

DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019

Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019

DEVELOPMENT OF A CELLULAR MODEL OF ACUTE MYELOID LEUKEMIA THROUGH CRISPR/CAS 9 TECHNOLOGY

Romero, EG; (...); Zamora, JVC

Meeting Abstract. 2017

DEVELOPMENT OF A MASSIVE SEQUENCING TEST FOR THE SIMULTANEOUS DETECTION OF POTENTIAL MUTATIONS AND CHROMOSOMAL ALTERATIONS IN PATIENTS WITH MYELODISPLASIC SYNDROMES

Liquori, A.; (...); Zamora, JVC

Meeting Abstract. 2017

Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model

Diaz-Garcia, C; (...); Pellicer, A

Article. 10.1093/humrep/dez115. 2019

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Döhner H; (...); Bloomfield, CD

Review. 10.1182/blood-2016-08-733196. 2017

DIAGNOSIS OF NOONAN SYNDROME AFTER STUDY OF NGS BY ESSENTIAL THROMBOCITEMIA

Marco Ayala, J.; (...); Sanz, M. A.

Meeting Abstract. 2018

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Spanish PETHEMA Grp

Article. 10.4084/MJHID.2019.016. 2019

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.

Montesinos P; (...); DiNardo CD

Article. 10.1182/bloodadvances.2023011914. 2024

Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.

Fathi, Amir T; (...); de Botton, Stephane

Review. 10.1002/ajh.26142. 2021

Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.

Asensi Cantó P; (...); Guerreiro M

Article. 10.1111/tid.14067. 2023

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

Suárez EU; (...); Montesinos P

Article. 10.1007/s00277-024-05840-7. 2024

Dose banding aplicado a la elaboracion de antineoplasicos: una revision narrativa de la literatura.

Pérez Huertas P; (...); Poveda Andrés JL

Article. 10.7399/fh.2015.39.4.8839. 2015

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Hutchings, Martin; (...); Subklewe, Marion

Meeting Abstract. 10.1182/blood-2023-173302. 2023

Drug Interaction Between Oral Cyclosporine Modified and Iron

Domingo-Chiva, E; (...); Poveda-Andres, JL

Article. 10.1177/1060028013514734. 2014

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/17512433.2023.2174523. 2023

Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Review. 10.1007/s00277-020-04186-0. 2020

Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases

Review. 10.1007/s10072-017-2833-9. 2017

EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases

Sanz J; (...); Sanz GF

Article. 10.1038/bmt.2013.190. 2014

ECONOMIC IMPACT LINKED TO THE REDUCTION OF EXACERBATIONS WHEN A TREATMENT REGIME WITH INHALED ANTIBIOTICS IS SWITCHED TO AZTREONAM LYSINE IN PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC PULMONARY INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA

Sole A; (...); Casado MA

Meeting Abstract. 10.1016/j.jval.2014.08.1659. 2014

Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018

Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome

Cañigral C; (...); Sanz MA

Letter. 10.1007/s00277-013-1970-3. 2014

Editorial introductions

Curigliano, Giuseppe; (...); Mateos, Maria-Victoria

Editorial Material. 10.1097/CCO.0000000000001001. 2023

Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020

Effect of CD8(+) Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies

Moscardó F; (...); Sanz GF

Article. 10.1016/j.bbmt.2014.06.038. 2014

EFFECT OF CYP3A5 GENOTYPE ON TACROLIMUS DOSE REQUIREMENT, NEPHROTOXICITY AND ACUTE REJECTION IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES

Rojas, L.; (...); Alino, S. F.

Article. 2013

Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies

Rojas L; (...); Aliño SF

Article. 10.1038/tpj.2014.38. 2015

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

Dinardo, CD; (...); Dohner, H

Meeting Abstract. 2020

Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (RR) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2019

EFFECT OF MISSENSE MUTATIONS IN THE SPLICING OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA

Morote-Faubel, M.; (...); Cervera, J.

Meeting Abstract. 2019

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7006. 2021

EFFECTIVENESS AND TOXICITY OF THE USE OF INOTUZUMAB (INO) IN PATIENTS WITH RESISTANT OR RECALLING (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (LAL). STUDY OF PATIENTS INCLUDED IN INO'S EXPANDED USE PROGRAM

Ribera Santasusana, J. M.; (...); Valero, M.

Meeting Abstract. 2021

Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021

EFFECTS OF POLYMORPHIMS OF CYP3A5 AND ABCB1 GENES ON CHRONIC NEPHROPATHY: COHORT STUDY

Rojas, L.; (...); Alino, S. F.

Article. 2013

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia

Ribera, JM; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1397661. 2018

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1182/blood-2018-99-110439. 2018

Efficacy and Safety of Single-Agent Quizartinib (Q), Potent and SeleEfficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 2019

Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Jonas, BA; (...); Levis, MJ

Meeting Abstract. 10.1016/j.clml.2019.07.097. 2019

eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/14728214.2021.2009800. 2022

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.

Smith CC; (...); Bahceci E

Article. 10.1182/blood-2019-122620. 2019

Emerging strategies for the treatment of older patients with acute myeloid leukemia

Sanz MA; (...); Venditti A

Review. 10.1007/s00277-016-2666-2. 2016

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

DiNardo CD; (...); Döhner H

Article. 10.1016/S1470-2045(21)00494-0. 2021

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.

de Botton, Stephane; (...); DiNardo, Courtney D.

Article. 10.1182/blood.2021014901. 2022

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Montesinos, Pau; (...); Recher, Christian

Meeting Abstract. 10.1182/blood-2024-194356. 2024

Enhancing roasted pepper quality sustainably: Impact of biodegradable mulches

Guerra, Marcos; (...); Casquero, Pedro Antonio

Article. 10.1016/j.jafr.2024.101393. 2024

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

Estudio de utilizacion de boceprevir y telaprevir para el tratamiento de la hepatitis C cronica.

Marrero-Álvarez P; (...); Poveda-Andrés JL

Abstract of Published Item. 10.7399/FH.2014.38.1.1128. 2014

EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019

EVALUATION OF THE MUTATION OF FLT3 IN ACUTE MYELOID LEUKAEMIA: RESULTS OF THE DELPHI QUESTIONNAIRE OF THE SPANISH GROUP

Gomez-Casares, M. T.; (...); Sierra, J.

Meeting Abstract. 2019

Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Mosquera Orgueira, Adrian; (...); Perez Encinas, Manuel Mateo

Article. 10.3389/fonc.2022.968340. 2022

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan

Meeting Abstract. 10.1182/blood-2022-163016. 2022

Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.

Labrador, Jorge; (...); Montesinos, Pau

Article. 10.1002/cncr.35431. 2024

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

Boluda B; (...); Montesinos P

Article. 10.1080/10428194.2021.1938031. 2021

Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1038/s41375-020-01058-4. 2020

Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.

Montoro, Juan; (...); Sanz, Jaime

Article. 10.1111/ejh.13529. 2021

Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 10.1016/j.gastrohep.2014.05.004. 2014

Experience of Home Delivery Program in Haemophilia Through an Association of Patients

Megias Vericat, J. E.; (...); Bonanad Boix, S.

Meeting Abstract. 2017

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Pemmaraju, Naveen; (...); Daver, Naval

Meeting Abstract. 10.1182/blood-2021-146666. 2021

EXPERTS CONSENSUS ON THE FUTURE OF RARE DISEASES CARE AND ORPHAN DRUGS ACCESS IN SPAIN: A DELPHI STUDY

Paz S; (...); Urcelay J

Meeting Abstract. 10.1016/j.jval.2015.09.2016. 2015

Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180710. 2023

EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019

Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.1002/jca.21901. 2021

Ex-vivo T-cell depleted peripheral blood stem cell transplantation from HLA-matched sibling donors for the treatment of severe aplastic anemia

Cano-Ferri, I.; (...); Sanz, G.

Meeting Abstract. 2015

Factors Associated With Survival in Secondary Acute Myeloid Leukemia in Colombia

Sossa, Claudia; (...); Marcela Cuervo, Diana

Meeting Abstract. 2023

Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation

Solves P; (...); Carpio N

Article. 10.1007/s00277-017-3168-6. 2018

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Ribera JM; (...); Sancho JM

Article. 10.3324/haematol.2023.283342. 2024

Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group

Ribera, JM; (...); Spanish Soc Hematology

Article. 10.1016/j.leukres.2015.11.012. 2016

Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019

Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021

FINAL RESULTS OF THE LAL-RI 08 PROTOCOL FOR ADOLESCENTS AND YOUNG ADULTS (AAJ) WITH LYMPHOBLASTIC ACUTE LEUKEMIA (LAL) OF STANDARD RISK (RE)

Santasusana, JMR; (...); Vale, AODCE

Meeting Abstract. 2018

First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).

Jabbour, Elias; (...); Ribera, Josep-Maria

Meeting Abstract. 2023

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Jabbour, Elias; (...); Ribera, Jose-Maria

Meeting Abstract. 2023

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Salamero, Olga; (...); Somervaille TCP

Article. 10.1200/JCO.19.03250. 2020

FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET.

Venditti, Adriano; (...); Ossenkoppele, Gert J

Article. 10.1182/bloodadvances.2024013744. 2025

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk

Spina M; (...); FLORENCE Study Group

Article. 10.1093/annonc/mdv317. 2015

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

Pallarès V; (...); Casanova, I

Article. 10.3390/cancers10110436. 2018

Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7013. 2021

Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2022

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Perl AE; (...); Levis MJ

Article. 10.1182/blood.2021011583. 2022

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

Genesca, E; (...); Ribera, JM

Article. 10.1186/s13045-018-0639-8. 2018

FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN AN ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH PETHEMA GROUP PROTOCOLS

Genesca, E; (...); Ribera, JM

Meeting Abstract. 2017

Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia

Motllo C; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1326596. 2018

Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

Motlló C; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2016.1177182. 2017

Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain.

Ribera, Josep-Maria; (...); Pinana, Jose-Luis

Article. 10.1016/j.clml.2021.06.024. 2021

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Cortes, JE; (...); Baer, MR

Meeting Abstract. 10.1182/blood-2018-99-114126. 2018

FUNCTIONAL CLASSIFICATION OF DEEP INTRONIC VARIANTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2019

FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Morote-Faubel, Mireya; (...); Cervera, Jose

Meeting Abstract. 2020

FUNCTIONAL STUDY OF SILENCED HMGCR GENE IN CELL LINES OF ACUTE MYELOID LEUKEMIA PATIENTS

De Matteo, B; (...); Zamora, JVC

Meeting Abstract. 2017

GAM: General Auxetic Metamaterial with Tunable 3D Auxetic Behavior Using the Same Unit Cell Boundary Connectivity

Ben-Yelun, Ismael; (...); Saucedo-Mora, Luis

Article. 10.3390/ma16093473. 2023

Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.

Eirís J; (...); Sanz J

Article. 10.1016/j.jtct.2024.10.009. 2024

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial

Ravandi, Farhad; (...); Dombret, Herve

Meeting Abstract. 2020

Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial

Pfeilstocker, M.; (...); Dombret, H.

Meeting Abstract. 2021

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

Mosquera Orgueira A; (...); Bello López JL

Article. 10.1371/journal.pone.0247093. 2021

GENES BELONGING TO THE SWI/SNF CHROMATIN REMODELING COMPLEXES ARE MUTATED AT HIGH FREQUENCY IN RARE T(11;17)(Q23;Q21)/ZBTB16-RARA ACUTE MYELOID LEUKEMIA PATIENTS

Fabiani, E.; (...); Voso, M. T.

Meeting Abstract. 2020

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024

GENOME-WIDE ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISM (SNPS) IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE

Ibanez, M.; (...); Cervera, J.

Meeting Abstract. 2016

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)

Lin, Wei-Yu; (...); Allan, James M.

Article. 10.1038/s41467-021-27679-6. 2022

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Lin WY; (...); Allan JM

Article. 10.1038/s41467-021-26551-x. 2021

Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain

Lalaoui, R; (...); Rolain, JM

Article. 10.1186/s13756-019-0630-3. 2019

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil, Celia; (...); Genesca, Eulalia

Article. 10.3324/haematol.2022.281196. 2023

Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population

Bosó V; (...); Aliño SF

Article. 10.1097/FTD.0b013e3182a94e65. 2014

Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants.

Mannan A; (...); Aljurf M

Article. 10.1016/j.hemonc.2020.05.007. 2020

GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS

Santiago, M.; (...); Cervera-Zamora, J.

Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023

GETH-CLL4: Long-term follow-up of a pilot trial evaluating the addition of ofatumumab to the conditioning regimen of patients with chronic lymphocytic leukemia undergoing allogeneic HCT

Montesinos, Pau; (...); Delgado, Julio

Meeting Abstract. 2018

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.

Perl AE; (...); Levis MJ

Article. 10.1056/NEJMoa1902688. 2019

Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML comutations or a high FLT3-internal tandem duplication allelic ratio

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2020

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial

Perl, AE; (...); Levis, MJ

Meeting Abstract. 10.1158/1538-7445.AM2019-CT184. 2019

GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

Ballesta-López O; (...); Montesinos P

Review. 10.2217/fon-2020-0700. 2020

Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.

Sekeres MA; (...); Cortes JE

Article. 10.1038/s41375-023-02001-z. 2023

Glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): BRIGHT AML 1003 final report and 4-year overall survival follow-up

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib Plus Low-Dose Cytarabine in Acute Myeloid Leukemia or Myelodysplastic Syndrome: BRIGHT AML 1003 Final Report and 4-Year Overall Survival Follow-Up

Heuser, Michael; (...); Cortes, Jorge E.

Meeting Abstract. 2020

Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone

Wang, ES; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.114. 2019

Glomerulonephritis Secondary to Acute Promyelocytic Leukemia that Resolved after Induction Therapy.

Andres Regino, Carlos; (...); Angel Sanz, Miguel

Article. 10.1159/000528088. 2023

Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022

Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia.

Lozano ML, Sanz MA, Vicente V

Article. 10.1016/j.medcli.2021.03.017. 2021

Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017

Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

López Rubio M; (...); Garcia-Marco JA

Article. 10.3109/10428194.2013.827187. 2014

Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML

Kwon M; (...); Diez-Martin JL

Article. 10.1038/bmt.2017.36. 2017

Haploidentical non-manipulated stem cell transplant in patients with non-hodgkin lymphoma: Spanish experience

Dorado, N; (...); Diez-Martin, JL

Meeting Abstract. 2019

Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018

Hazardous drugs: new challenges, new opportunities.

Valero García S; (...); Poveda Andrés JL

Article. 10.7399/fh.2016.40.2.10462. 2016

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.

Solana-Altabella A; (...); Montesinos P

Article. 10.1111/ejh.13604. 2021

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

DiNardo, Courtney D.; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-147601. 2021

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Dinardo, Courtney Denton; (...); De Botton, Stephane

Meeting Abstract. 2022

Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.

Dohner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 2022

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

Huang XJ; (...); Issaragrisil S

Article. 10.18632/oncotarget.15655. 2017

Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.

Sanz, Jaime; (...); Marrow Transplantation (EBMT)

Article. 10.1038/s41409-020-01162-0. 2020

High Delta Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia

Lucena-Araujo AR; (...); Rego EM

Article. 10.1182/blood-2015-01-623330. 2015

High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous $\beta$-Lactams.

Djukovic, Ana; (...); Ubeda, Carles

Article. 2020

High heterogeneity of multidrug-resistant Enterobacteriaceae fecal levels in hospitalized patients is partially driven by intravenous beta-lactams.

Djukovic A; (...); Ubeda C

Article. 10.1128/AAC.01415-19. 2020

High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022

History of Acute Promyelocytic Leukemia.

Sanz MA, Barragán E

Article. 10.2991/chi.k.210703.001. 2021

Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022

Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021

How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

Sanz MA, Montesinos P

Review. 10.1182/blood-2013-10-512640. 2014

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M; (...); Zeidan AM

Article. 10.1182/bloodadvances.2018016121. 2018

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-152183. 2021

Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.

Salamero, Olga; (...); Montesinos, Pau

Article. 10.1016/S2352-3026(24)00132-7. 2024

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial.

Konopleva, Marina Y.; (...); Wei, Andrew H.

Article. 10.1182/bloodadvances.2021006303. 2022

Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia

Pinero, Paula; (...); Tarin, Fabian

Article. 10.3390/cancers14164010. 2022

Identifying prognostic gene panels in acute myeloid leukemia.

Sanchez-Garcia, Joaquin; (...); Montesinos, Pau

Article. 10.1080/17474086.2023.2193322. 2023

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Review. 10.2147/BLCTT.S177913. 2019

IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION

Eiris, Juan; (...); Balaguer-Rosello, Aitana

Meeting Abstract. 2024

Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.

Cordón L; (...); Sanz J

Article. 10.1007/s00277-024-05758-0. 2024

Immunohaematological events related to changes in haematic and seric ABO group in patients undergoing haematopoietic stem cell transplantation with major ABO mismatch.

Santiago, M; (...); Solves, P

Letter. 10.1111/tme.12538. 2019

Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis

Edo Solsona MD; (...); Poveda Andrés JL

Article. 10.2147/PPA.S127508. 2017

IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS

Edo-Solsona, M.; (...); Poveda-Andres, J.

Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016

IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Ibanez, Mariam; (...); Sanz, Guillermo

Meeting Abstract. 2020

Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 10.1182/blood-2022-169011. 2022

IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

Impact of an antimicrobial stewardship program on critical haematological patients.

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.7399/fh.2017.41.4.10709. 2017

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

Barba P; (...); Ribera JM

Article. 10.1097/HS9.0000000000000810. 2023

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Article. 10.1080/10428194.2020.1839650. 2020

IMPACT OF CYTOGENETIC ABNORMALITIES DEFINING AML MYELODYSPLASIA-RELATED (WHO AND ICC 2022) IN FIRST LINE DECITABINE IN UNFIT AML PATIENTS

de la Fuente, Adolfo; (...); Tormo, Mar

Meeting Abstract. 2023

Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.

Ayala, Rosa; (...); Montesinos, Pau

Article. 10.3390/cancers14235799. 2022

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Matteuzzi, Tommaso; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2021-152215. 2021

Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation.

Sanz J; (...); GETH and GITMO

Article. 10.1016/j.bbmt.2013.07.004. 2013

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

Rubio, MT; (...); Nagler, A

Article. 10.1186/s13045-016-0389-4. 2017

Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort

Stahl, M; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-112495. 2018

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.

Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop

Article. 10.1038/s41375-021-01126-3. 2021

Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation

Tucunduva L; (...); Rocha V

Article. 10.1111/bjh.12970. 2014

Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018

Impact of natural-killer immune reconstitution on the development of cytomegalovirus infection, non-relapse mortality, and graft versus host disease after allogeneic stem cell transplantation

Rodriguez-Veiga, R.; (...); Sanz, M. A.

Meeting Abstract. 2015

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017

Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.

Döhner K; (...); Bloomfield CD

Article. 10.1182/blood.2019002697. 2020

IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.

Marco-Ayala, Javier; (...); Solves, Pilar

Article. 10.1016/j.jtct.2023.01.009. 2023

Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation

Ruiz J; (...); Aliño SF

Article. 10.3390/ijms160920168. 2015

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020

Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia

Barba P; (...); Ribera JM

Article. 10.3109/10428194.2015.1014365. 2015

Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Meeting Abstract. 2015

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.

Kayser, Sabine; (...); Schlenk, Richard F.

Article. 10.3324/haematol.2022.282127. 2023

Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019

Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation

Sanz J; (...); Sanz GF

Article. 10.1016/j.bbmt.2013.10.016. 2014

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Marconi, Giovanni; (...); Martinelli, Giovanni

Meeting Abstract. 10.1182/blood-2023-184745. 2023

Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020

IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING

Simarro, CS; (...); Gonzalez, EB

Meeting Abstract. 2017

Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018

Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil

de la Rubia, Javier; (...); Sanz, Miguel

Meeting Abstract. 2023

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.

Onecha E; (...); Ayala R

Article. 10.1111/bjh.16432. 2020

In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene

Such E; (...); Sanz MA

Letter. 10.1007/s00277-014-2073-5. 2014

IN VIVO MODELS FOR THE FUNCTIONAL STUDY OF CO-OCCURRING GENETIC AND EPIGENETIC MUTATIONS IN MYELODYSPLASTIC SYNDROMES

Martinez-Valiente, C.; (...); Sanjuan-Pla, A.

Meeting Abstract. 2018

IN VIVO MODELS TO STUDY THE COOPERATION BETWEEN SPLICING AND DNA METHYLATION IN MYELODYSPLASTIC SYNDROMES

Martinez-Valiente, Cristina; (...); Sanjuan-Pla, Alejandra

Meeting Abstract. 2020

INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONS DURING THE THERAPY OF INDUCTION IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NEW DRUGS. STUDY OF 67 PATIENTS FROM A SINGLE CENTRE

Martinez Garcia, M. F.; (...); Sanz Alonso, M. A.

Meeting Abstract. 2015

Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group

Ribera, Josep-Maria; (...); Feliu, Evarist

Article. 10.1002/cncr.32156. 2019

Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.

Rodríguez-Veiga R; (...); Sanz GF

Article. 10.1007/s00277-019-03744-5. 2019

Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.3390/cancers15082267. 2023

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis

Montesinos P; (...); Sanz MA

Article. 10.1038/bmt.2015.181. 2015

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

Kelleher, N; (...); Spanish Soc Hematology

Article. 10.3109/10428194.2015.1040013. 2016

Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.

Asensi Cantó P; (...); Sanz J

Article. 10.1038/s41409-024-02391-3. 2024

Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients

Pinana JL; (...); Sanz MA

Article. 10.1007/s00277-013-1872-4. 2014

Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients

Pinana, JL; (...); Navarro, D

Article. 10.1111/tid.13158. 2019

Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.

Chorao, Pedro; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2024.12.006. 2024

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.

Sobas, Marta; (...); Montesinos, Pau

Article. 10.1007/s00277-023-05582-y. 2023

Incompatibility of undiluted busulfan injection with a needle-free valve

Cueto-Sola, M; (...); Poveda-Andres, JL

Letter. 10.2146/ajhp140111. 2014

Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials

Barba, P; (...); Ribera, JM

Article. 10.1111/ejh.13178. 2019

In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph plus ALL.

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.6533. 2024

In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph plus ALL

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. 10.1016/S2152-2650(24)00426-9. 2024

Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018

Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago

Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Labrador, Jorge; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-162591. 2022

Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation

Balaguer Rosello A; (...); Sanz, J

Article. 10.1016/j.bbmt.2016.10.005. 2017

INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN THE ALOGENIC TRANSPLANTATION OF HEMATOPOYETIC PROGENITORS

Balaguer Rosello, A.; (...); Sanz Caballer, J.

Meeting Abstract. 2018

Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies

Megías-Vericat JE; (...); Aliño SF

Review. 10.1038/tpj.2014.80. 2015

Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017

Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Article. 10.1097/FPC.0000000000000431. 2021

Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia

Meeting Abstract. 2015

Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study

Boluda, Blanca; (...); Sanz, Miguel A.

Meeting Abstract. 10.1182/blood.V128.22.1614.1614. 2016

INHIBITORS OF THE MUTATED DEHYDROGENASE (MIDH), IVOSIDENIB OR ENASIDENIB, IN COMBINATION WITH AZACITINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

Montesinos, P; (...); Vyas, P

Meeting Abstract. 2018

IN-SILICO AND IN VITRO STUDY OF MUTATIONS THAT ALTER THE SPLICING PROCESS IN PATIENTS WITH MYELODISPLASIC SYNDROMES

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2019

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.

Simoes C; (...); Paiva B

Article. 10.1182/bloodadvances.2022008141. 2023

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

Elena C; (...); Cazzola M

Article. 10.1182/blood-2016-05-714030. 2016

INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD

De la Fuente, A.; (...); Montesinos, P.

Meeting Abstract. 2019

Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.

Bermejo San José F; (...); Sanromán-Álvarez L

Article. 10.7399/fh.2016.40.5.10180. 2016

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study

Lucena-Araujo AR; (...); Rego EM

Article. 10.1007/s00277-014-2142-9. 2014

International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Roboz GJ; (...); Giles FJ

Article. 10.1200/JCO.2013.52.8562. 2014

Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019

Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Nagler A; (...); Mohty M

Article. 10.3324/haematol.2014.105197. 2014

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

Blanes, M; (...); de la Rubia, J

Letter. 10.1007/s00277-019-03663-5. 2019

Intravenous Busulfan-Melphalan vs Melphalan as Preparative Regimen for Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of a Case-Control Study

Blanes, M; (...); de la Rubia, J

Meeting Abstract. 10.1016/j.clml.2019.09.473. 2019

Intravenous busulphan plus melphalan versus melphalan alone as conditioning regimen for newly diagnosed patients with multiple myeloma: Long-term follow-up of a matched case-controlled study

Blanes, M; (...); de la Rubia, J

Meeting Abstract. 2019

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen

Montoro, J; (...); Pinana, JL

Article. 10.1111/ejh.13202. 2019

INVASIVE FUNGAL INFECTION IN ADULT PATIENTS SUBMITTED TO UMBILICAL CORD BLOOD TRANSPLANTATION

Montoro, J.; (...); Pinana, J. L.

Meeting Abstract. 2018

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024

Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024

Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation

Solves, P; (...); Sanz, MA

Letter. 10.1111/tme.12386. 2017

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Montesinos, Pau; (...); Dohner, Hartmut

Article. 10.1056/NEJMoa2117344. 2022

Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.

Montesinos, Pau, de Botton, Stephane, Dohner, Hartmut

Letter. 10.1056/NEJMc2206489. 2022

Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study

de Botton, Stephane; (...); Doehner, Hartmut

Meeting Abstract. 2023

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Montesinos, Pau; (...); Dombret, Herve

Meeting Abstract. 10.1182/blood-2023-187286. 2023

ladademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-168945. 2022

Live donor kidney transplantation. Situation analysis and roadmap.

de la Oliva Valentín M; (...); Domínguez-Gil B

Article. 10.1016/j.nefroe.2022.02.002. 2022

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.

Meeting Abstract. 10.1182/blood-2019-129274. 2019

Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy plus Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy

Caceres, S; (...); Burgues, JMMB

Meeting Abstract. 10.1182/blood-2018-99-116924. 2018

Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.

Sanz, Miguel Angel; (...); Sanz, Jaime

Article. 10.1038/s41409-024-02319-x. 2024

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

Martínez-Cuadrón D; (...); Sanz MA

Article. 10.1038/leu.2017.178. 2018

Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato

Article. 10.1016/j.jtct.2020.12.029. 2021

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Recher, Christian; (...); Montesinos, Pau

Article. 10.1038/s41375-021-01425-9. 2022

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.

Wei, Andrew H.; (...); Roboz, Gail J.

Letter. 10.1002/ajh.26847. 2023

Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Papayannidis, C; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.111. 2019

Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.

Smith, BD; (...); Cortes, JE

Meeting Abstract. 2019

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Zeidner, Joshua F; (...); Vyas, Paresh

Article. 10.1182/blood.2024027408. 2025

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Sanz, MA; (...); Lo-Coco, F

Article. 10.1182/blood-2019-01-894980. 2019

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Ravandi, F; (...); Dombret, H

Article. 10.1186/s13045-021-01142-x. 2021

Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.

Stahl M; (...); Zeidan AM

Article. 10.1038/s41375-020-0783-3. 2020

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022

MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA

Sargas Simarro, C.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021

Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia

Sanz MA; (...); Perales A

Article. 10.1007/s00277-015-2372-5. 2015

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.

Simoes C; (...); Montesinos P

Article. 10.1182/bloodadvances.2020003195. 2021

Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.

Rojas LE; (...); Aliño SF

Article. 10.1097/FPC.0b013e3283642fb3. 2013

Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022

Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

Voso MT; (...); Lo-Coco F

Article. 10.1182/bloodadvances.2020002904. 2020

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Stone, RM; (...); Döhner H

Article. 10.1056/NEJMoa1614359. 2017

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

Sierra, Jorge; (...); Venditti, Adriano

Article. 10.1182/bloodadvances.2023009847. 2023

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.

Larson RA; (...); Stone RM

Article. 10.1038/s41375-021-01179-4. 2021

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Alfonso Pierola, Ana; (...); Prosper, Felipe

Meeting Abstract. 10.1182/blood-2023-188865. 2023

Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

Vidriales, MB; (...); PETHEMA Programa Estudio Terapeuti

Article. 10.1016/j.leukres.2015.10.002. 2016

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine +/- idasanutlin in relapsed or refractory acute myeloid leukemia

Montesinos, P; (...); Fenaux, P

Article. 10.2217/fon-2020-0044. 2020

MIRROS: An ongoing randomized phase 3 trial of idasanutlin plus ARA-C in patients with relapsed or refractory acute myeloid leukemia.

Montesinos, P; (...); Fenaux, P

Meeting Abstract. 2019

MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL

Gonzalez-Romero, E.; (...); Cervera-Zamora, J.

Meeting Abstract. 2021

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH(1) Acute Myeloid Leukemia

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1182/blood-2021-144912. 2021

MOLECULAR CHARACTERIZATION OF ACUTE LEUKAEMIA OF CHILD, ADOLESCENT AND YOUNG ADULT THROUGH MASSIVE GUIDED SEQUENCING

Llop Garcia, M.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

MOLECULAR CHARACTERIZATION OF CELLULAR MODELS OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BY MASS SEQUENCING

Navarro, MB; (...); Cervera, J

Meeting Abstract. 2017

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo plus AZA in the AGILE Study

Doehner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-159473. 2022

Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.

De Botton, Stephane; (...); Dohner, Hartmut

Meeting Abstract. 2022

MOLECULAR CHARACTERIZATION OF VARIANTS THAT ALTER SPLICING (VAS) IN PATIENTS WITH MYELODYSPLASIC SYNDROMES

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2020

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Rücker FG; (...); Doehner, Konstanze

Article. 10.1038/s41375-021-01323-0. 2021

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.

Sargas, Claudia; (...); On Behalf Of Pethema Group

Article. 10.3390/cancers15020438. 2023

Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Ribera J; (...); Ribera JM

Article. 10.1002/gcc.22788. 2019

Molecular remission as a therapeutic objective in acute promyelocytic leukemia

Cicconi, L; (...); Lo-Coco, F

Review. 10.1038/s41375-018-0219-5. 2018

Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021

Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021

MONITORING MINIMUM RESIDUAL DISEASE (EMR) THROUGH NGS CONFIRMS PROGNOSTIC VALUE

De La Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018

MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients

Olivera, GG; (...); Herrero, MJ

Article. 10.3390/ijms21082714. 2020

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Lin, Chenyu; (...); Horwitz, Mitchell E.

Article. 10.1016/j.jtct.2023.01.031. 2023

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3(mut+)) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Esteve, J; (...); Bahceci, E

Meeting Abstract. 10.1182/blood-2018-99-110976. 2018

Multicentre Implementation of Next Generation Sequencing to Acute Myeloid Leukemia Patients in PETHEMA Spanish Collaborative Group

Sargas, C; (...); Barragan, E

Meeting Abstract. 2019

Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021

Multiomics Characterization of Normal CD34+Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)

Simoes, Catia; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-185760. 2023

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

Sánchez-García J; (...); Sanz GF

Article. 10.1111/bjh.12876. 2014

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).

Dinardo, CD; (...); Vyas, P

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7042. 2018

Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia

Fabiani E; (...); Voso MT

Article. 10.1002/cam4.3904. 2021

Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms.

Sanz J; (...); Brunstein C

Article. 10.1016/j.bbmt.2013.09.015. 2013

N. VICTOR JIMENEZ TORRES (1942-2015) IN MEMORIAM

Climente Martí M, Poveda Andrés JL, Culebras J

Biographical-Item. 10.3305/nh.2015.32.4.9704. 2015

NATIONAL EXPERIENCE WITH THE USE OF VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Labrador, J.; (...); Montesinos, P.

Meeting Abstract. 2020

National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

Pallares, V; (...); Mangues, R

Article. 10.18632/oncotarget.18537. 2017

Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS)

Martin, I; (...); Sanz, G

Article. 10.1080/10428194.2016.1246725. 2017

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.

Sargas C; (...); Montesinos P

Article. 10.3324/haematol.2020.263806. 2021

NEUTROPHILIA AND ONCOGENE CSF3R MUTATION

Segarra, MG; (...); Alonso, MAS

Meeting Abstract. 2017

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES

Primo, D.; (...); Ballesteros, J.

Meeting Abstract. 2017

NGS ANALYSIS IN ADULTS GREATER THAN 65 YEARS DIAGNOSED OF ACUTE MYELOID LEUKEMIA IN LOW INTENSITY TREATMENTS

Garcia, AB; (...); Lopez, JM

Meeting Abstract. 2017

Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial

Horwitz, ME; (...); Sanz, G

Meeting Abstract. 10.1016/j.bbmt.2017.12.628. 2018

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Castano-Bonilla, Tamara; (...); Montesinos, Pau

Article. 10.1155/2022/3132941. 2022

Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Balaguer-Rosello, A; (...); Sanz, Jaime

Article. 10.1016/j.bbmt.2019.05.024. 2019

Non-infectious neurologic complications after allogeneic hematopoietic stem cell transplantation (ALLO-HSCT)

Balaguer Rosello, Aitana; (...); Sanz, Jaime

Meeting Abstract. 2019

Novel real-time polymerase chain reaction assay for simultaneous detection of recurrent fusion genes in acute myeloid leukemia.

Dolz S; (...); Sanz MA

Article. 10.1016/j.jmoldx.2013.04.003. 2013

Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies studies and correlation with flt3 mutations and polyunsaturated fatty acid metabolism.

Mazzarella L; (...); Pelicci PG

Article. 10.3324/haematol.2019.223925. 2020

OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA

Montesinos, P.; (...); Sanz, M.

Meeting Abstract. 2017

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Cortes, Jorge E.; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2021-144905. 2021

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.

de Botton, Stephane; (...); Cortes, Jorge

Article. 10.1182/bloodadvances.2022009411. 2023

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Cortes, Jorge E.; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-167330. 2022

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Watts, Justin M.; (...); Cortes, Jorge E.

Meeting Abstract. 10.1182/blood-2019-123920. 2019

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Watts, Justin M.; (...); Cortes, Jorge E.

Article. 10.1016/S2352-3026(22)00292-7. 2022

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

Cortes, Jorge E.; (...); Olutasidenib Combination Therapy Study Grp

Article. 10.1186/s13045-024-01657-z. 2025

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).

Cortes J; (...); Watts JM

Article. 10.1080/10428194.2024.2333451. 2024

Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023

One-Unit versus Two-Unit Cord-Blood Transplantation

Sanz, J, Sanz, GF, Sanz, MA

Letter. 2015

One-unit versus two-unit cord-blood transplantation.

Sanz J, Sanz GF, Sanz MA

Letter. 2015

Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018

OPTIMIZATION OF THE EFFICIENCY OF GENETIC EDITING OF HEMAPOYETIC PROGENITOR CELLS USING CRISPR/CAS9 RIBONUCLEOPROTEINS

Martinez-Valiente, C.; (...); Sanjuan-Pla, A.

Meeting Abstract. 2019

OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024

Oral Azacitidine (Oral-AZA) improves Overall Survival (OS) and Relapse-free Survival (RFS) for patients with Acute Myeloid Leukemia (AML) in first remission after Intensive Chemotherapy (IC), regardless of amount of consolidation received: Results of the QUAZAR AML-001 maintenance trial

Dohner, H.; (...); Ravandi, F.

Meeting Abstract. 2021

Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Wei, Andrew; (...); Roboz, Gail

Meeting Abstract. 2022

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Wei AH; (...); Roboz GJ

Article. 10.1056/NEJMoa2004444. 2020

Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.

Sobas M; (...); Giebel S

Article. 10.1016/j.clml.2019.09.616. 2020

Outcome of Acute Myeloid Leukemia with Inv(3)(Q21q26.2)/ T(3;3)(Q21;Q26.2). Experience of the Spanish PETHEMA and CETLAM Groups

Sitges, M; (...); CETLAM Cooperative Grp

Meeting Abstract. 2019

Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy.

Perez, Ariadna; (...); Pinana, Jose Luis

Article. 10.1007/s15010-024-02213-0. 2024

Outcome of older (=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Kayser S; (...); Montesinos P

Article. 10.1038/s41375-020-0758-4. 2020

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)

Kayser, Sabine; (...); Montesinos, Pau

Correction. 10.1038/s41375-021-01358-3. 2021

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party

Koenecke, C; (...); Finke, J

Letter. 10.1038/bmt.2016.97. 2016

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Article. 10.3324/haematol.2022.282506. 2024

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials

Ribera, JM; (...); PETHEMA Grp

Article. 10.1002/hon.2910. 2021

Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

DiNardo, Courtney D.; (...); de Botton, Stephane

Meeting Abstract. 10.1182/blood-2021-147593. 2021

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Venditti, Adriano; (...); Pullarkat, Vinod

Meeting Abstract. 10.1182/blood-2023-182045. 2023

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Shallis, RM; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-119755. 2018

Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

Ocio EM; (...); PETHEMA Group

Article. 10.3324/haematol.2015.129577. 2015

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.08.020. 2020

Passenger lymphocyte syndrome in liver transplant recipients: a description of 12 cases

Romero S; (...); Sanz MÁ

Article. 10.2450/2015.0148-14. 2015

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

Patient Reported Outcomes in Patients with Newly Diagnosed FLT3(mut+) acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone

Wang, Eunice S.; (...); Shah, Manasee V.

Meeting Abstract. 10.1182/blood-2021-144977. 2021

Patient-reported Outcomes in Adults With Newly Diagnosed Ph plus Acute Lymphoblastic Leukemia Treated With Ponatinib or Imatinib in Combination With Reduced-Intensity Chemotherapy: Results From the Phase III PhALLCON Study

Ashaye, Ajibade; (...); Guo, Shien

Meeting Abstract. 2024

PATTERNS OF RESCUE TREATMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED IN THE FIRST LINE WITH AZACITIDINE AND DECITABIN: RESULTS OF THE PETHEMA AML REGISTRY

Jorge, Labrador; (...); Miguel-Angel, Sanz

Meeting Abstract. 2021

PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.

González-Romero E; (...); Vázquez-Manrique RP

Article. 10.3390/cancers15174263. 2023

Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study

Rodriguez-Medina, C; (...); Fernandez, PM

Article. 10.1016/j.leukres.2020.106352. 2020

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Stahl, M; (...); Zeidan, AM

Letter. 10.1080/10428194.2018.1468893. 2019

Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling

Orgueira, AM; (...); Lopez, JLB

Article. 10.3389/fonc.2021.657191. 2021

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Sargas, Claudia; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-166639. 2022

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Review. 10.2174/1389200218666171101124931. 2018

Pharmacogenomics and the treatment of acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Review. 10.2217/pgs-2016-0055. 2016

Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples.

Primo, D; (...); Ballesteros, J

Meeting Abstract. 2017

Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine

Bennett TA; (...); Ballesteros J

Article. 10.1016/j.clml.2013.11.006. 2014

Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021

Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022

Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.

Calleja Hernández MÁ; (...); Aragon, B

Article. 10.7399/fh.2017.41.1.10463. 2017

Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).

Walker, Alison R.; (...); William Burke, Patrick

Meeting Abstract. 2022

Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial.

Martinelli, Giovanni; (...); Montesinos, Pau

Meeting Abstract. 2022

Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.

Wang, Eunice S.; (...); Tiu, V, Ramon

Article. 10.1182/blood.2021014586. 2022

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Wang, Eunice S.; (...); Tiu, Ramon V.

Meeting Abstract. 10.1182/blood-2021-145379. 2021

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide

Horwitz, ME; (...); Sanz, G

Article. 10.1200/JCO.18.00053. 2019

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia

Martínez-Cuadrón D; (...); Sanz MA

Article. 10.1007/s00277-013-1914-y. 2014

Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)

Querol-Fuentes, F; (...); Bonanad, S

Meeting Abstract. 2017

Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Daver NG; (...); Kantarjian HM

Article. 10.1016/S1470-2045(23)00674-5. 2024

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2023-173413. 2023

PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020

PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review

Sobas, M; (...); Montesinos, P

Review. 10.3390/cancers12051313. 2020

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1002/hem3.67. 2024

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA WITH PHILADELPHIA CHROMOSOME. RESULTS OF THE PONALFIL CLINICAL TRIAL WITH COMPLETE RECRUITMENT

Ribera, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2020

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIA CHROMOSOME. PRELIMINARY RESULTS OF THE PONALFIL CLINICAL TRIAL

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2019

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIC CHROMOSOME (LAL PH plus ). RESULTS OF THE PONALFIL CLINICAL TRIAL WITH MEDIUM 2-YEAR FOLLOW-UP

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2021

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Meeting Abstract. 10.1182/blood-2019-125558. 2019

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Aldoss, Ibrahim; (...); Jabbour, Elias

Meeting Abstract. 10.1182/blood-2023-179537. 2023

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Jabbour, Elias; (...); Ribera, Jose-Maria

Article. 10.1001/jama.2024.4783. 2024

Ponatinib, Chemotherapy, and Transplant in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1182/bloodadvances.2022007764. 2022

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

Megías-Vericat JE; (...); Aliño SF

Letter. 10.1038/tpj.2015.79. 2016

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.

Lazzari, Lorenzo; (...); Sanz, Jaime

Article. 10.1038/s41409-022-01725-3. 2022

Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation

Dietrich, S; (...); EBMT Lymphoma Working Party

Letter. 10.1038/leu.2016.125. 2016

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

Romero S; (...); Sanz J

Article. 10.1080/10428194.2018.1474462. 2019

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1007/s40261-019-00881-7. 2020

Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018

Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?

Review. 10.1080/17474086.2020.1818559. 2020

Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Ballesteros, J; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-115849. 2018

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy

Abla, O; (...); Sanz, MA

Article. 10.1007/s00277-017-3042-6. 2017

PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Shortt, Jake; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2022-166937. 2022

Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021

Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021

Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.

Cortes JE; (...); Wang ES

Review. 10.1186/s13045-020-00975-2. 2020

Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021

Prognosis and Survival of Acute Myeloid Leukemia: Experience of a Single Center in Colombia

Sossa, CL; (...); Jimenez, SI

Meeting Abstract. 10.1182/blood-2018-99-119927. 2018

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Caballero, Teresa; (...); Perez-Simon, Jose A.

Meeting Abstract. 10.1182/blood-2021-151533. 2021

PROGNOSIS VALUE OF MINIMAL DETECTABLE DISEASE (MDD) BY 2(nd) GENERATION ALLOGENIC PRE-TRANSPLANTATION CYTOMETRY IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Velazquez Teresa, Caballero; (...); Jose Antonio, Perez Simon

Meeting Abstract. 2021

Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).

Roboz, Gail J.; (...); Dohner, Hartmut

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7014. 2021

Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults

Article. 2014

Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy

Article. 2014

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts

Martin, I; (...); Sanz, G

Article. 10.1038/s41408-017-0016-9. 2017

Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)

Rucker, FG; (...); Dohner, K

Meeting Abstract. 10.1182/blood-2018-99-116149. 2018

Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study

Lucena-Araujo AR; (...); Rego EM

Article. 10.1111/bjh.12921. 2014

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Dohner, Hartmut; (...); de Menezes, Daniel Lopes

Meeting Abstract. 10.1182/blood-2021-147465. 2021

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Dohner, Hartmut; (...); Lopes de Menezes D

Article. 10.1182/blood.2022016293. 2022

Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Uriel Suarez, Edwin; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-167365. 2022

PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS

Megias Vericat, J. E.; (...); Sanz, M. A.

Article. 2015

Prognostic Significance of Complex Karyotype and Monosomal Karyotype in Adult Patients With Acute Lymphoblastic Leukemia Treated With Risk-Adapted Protocols

Motlló C; (...); Feliu E

Article. 10.1002/cncr.28950. 2014

Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

Ribera J; (...); Ribera JM

Article. 10.1002/cncr.29579. 2015

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.

Castaño-Bonilla T; (...); Montesinos, P

Article. 10.1038/s41598-021-00050-x. 2021

Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.

Caballero-Velazquez, Teresa; (...); Perez-Simon, Jose A.

Article. 10.3390/cancers15051609. 2023

PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2021

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.10.014. 2020

Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler

Sanz, Jaime, Montesinos, Pau, Sanz, Miguel A

Letter. 10.1097/DSS.0000000000001046. 2017

Pulmonary invasive fungal disease after community acquire respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients: Results from a prospective observational study

Pinana, Jose; (...); Navarro, David

Meeting Abstract. 2019

qMetforminintreatment Overcomes AT-Resistance in Acute Promyelocytic Leukemia Foxo3A Expression

Pereira-Martins, DA; (...); Rego, EM

Meeting Abstract. 10.1182/blood-2018-99-115068. 2018

Quality of thawed plasma inactivated with methylene blue after 48-hour storage

Balaguer A; (...); Sanz MÁ

Letter. 10.1016/j.transci.2014.11.005. 2015

Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018

QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)

Levis, Mark J.; (...); Perl, Alexander E.

Meeting Abstract. 2023

Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Levis, Mark J.; (...); Perl, Alexander

Meeting Abstract. 10.1182/blood-2022-162739. 2022

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction ( IND) and Consolidation CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts)

Perl, Alexander; (...); Levis, Mark J.

Meeting Abstract. 10.1182/blood-2023-186785. 2023

QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2024

QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Erba, Harry P.; (...); Montesinos, Pau

Meeting Abstract. 2024

QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Schlenk, R; (...); Erba, H

Meeting Abstract. 2017

QuANTUM-R: phase 3, randomised trial of Quizartinib in patients with FLT3-Internal tandem duplication (FLT3-ITD)-positive relapsed/refractory (R/R) acute myeloid meukaemia (AML)

Radsak, M. P.; (...); Levis, M. J.

Meeting Abstract. 2019

Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1093/annonc/mdz374.003. 2019

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

Erba, Harry P.; (...); Schlenk, Richard F.

Article. 10.1016/S0140-6736(23)00464-6. 2023

Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML

Schlenk, R.; (...); Erba, H.

Meeting Abstract. 2022

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Cortes, JE; (...); Levis, MJ

Article. 10.1016/S1470-2045(19)30150-0. 2019

Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis

Vallejo C; (...); Rayón C

Article. 10.1007/s00277-015-2305-3. 2015

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Cortes, JE; (...); Heuser, M

Article. 10.1038/s41375-018-0312-9. 2019

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Voso, MT; (...); Lo-Coco, F

Meeting Abstract. 10.1182/blood-2018-99-114318. 2018

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA plus )

Falantes, J; (...); European ALMA?+?Investigators

Article. 10.1080/10428194.2017.1365854. 2018

Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.

Salamero O; (...); PETHEMA and PALG Groups

Article. 10.1080/10428194.2019.1607327. 2019

Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Saiz-Rodriguez, M; (...); Pethema Grp

Meeting Abstract. 2021

REAL-LIFE EVIDENCE OF VENETOCLAX TREATMENT IN PATIENTS WITH ACUTE REPLAPSE OR REFRACTORY LEUKEMIA MYELOID

Jorge, Labrador; (...); Pau, Montesinos

Meeting Abstract. 2021

Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.

Asensi Cantó P; (...); Gómez-Seguí I

Article. 10.1016/j.jtct.2023.09.001. 2023

Real-world experience with CPX-351 in high-risk acute myeloid leukemia.

Lemoli, Roberto M., Montesinos, Pau, Jain, Akriti

Article. 10.1016/j.critrevonc.2023.103984. 2023

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged = 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Requena, Gaspar Aspas; (...); Matinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-190128. 2023

Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015

Gonzalez, J; (...); Cohort Spanish HIV Res Network Co

Article. 10.1016/j.eimc.2019.02.007. 2019

Recommendations for the use of methotrexate in patients with juvenile idiopathic arthritis

Calvo I; (...); Díaz Cordovés-Rego G

Editorial Material. 10.1016/j.anpedi.2015.05.005. 2016

Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2023.07.008. 2023

Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia.

Weinhäuser I; (...); Rego EM

Article. 10.3390/cancers12113134. 2020

Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Baron F; (...); Mohty M

Article. 10.1002/cncr.29163. 2015

Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.

Cuéllar Monreal MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.2017.41.1.10434. 2017

Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.

Montesinos, Pau; (...); Heuser, Michael

Article. 10.3390/cancers16101824. 2024

REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?

Santiago, Marta; (...); Cervera, Jose

Meeting Abstract. 2020

Reply.

Lozano Almela, Maria Luisa, Sanz Alonso, Miguel Angel, Vicente Garcia, Vicente

Letter. 10.1016/j.medcli.2021.09.029. 2022

RESCUE TREATMENT WITH DECITABINE AFTER PROGRESSION TO AZACITIDINE IN AML

De la Fuente, A; (...); Montesinos, P

Meeting Abstract. 2018

Results of a preoperative autologous blood donation program for patients undergoing elective major spine surgery.

Solves P; (...); Sanz MA

Article. 10.1016/j.transci.2013.06.016. 2013

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Kantarjian, Hagop M.; (...); Chiao, Judy H.

Article. 10.1002/cncr.33828. 2021

Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.

Torrent, Anna; (...); Ribera, Josep-Maria

Article. 10.1111/ejh.14031. 2023

RESULTS OF THE TREATMENT OF LYMPHOBLASTIC LYMPHOMA WITH PROTOCOLS OF LYMPHOBLASTIC ACUTE LEUKEMIA OF PETHEMA GROUP

Sagues, M.; (...); Ribera, J. M.

Meeting Abstract. 2019

RETROSPECTIVE STUDY OF AZACITIDINE IN PATIENTS OF ADVANCED AGE WITH ACUTE MYELOID LEUKEMIA (LMA). RESULTS OF THE ALMA/ PETHEMA COHORT IN COMPARISON WITH THE MRC RISK INDEX SCORE

Falantes, J.; (...); Ramos, F.

Meeting Abstract. 2015

Revealing the mutational landscape of acute promyelocytic leukemia

Cervera, J, Sanz, MA

Editorial Material. 10.21037/tcr.2017.02.47. 2017

Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification.

Angenendt, Linus; (...); Schliemann, Christoph

Article. 10.1182/blood.2022018582. 2022

Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Tucunduva L; (...); Rocha V

Article. 10.1038/bmt.2014.72. 2014

Risk of Rh (D) alloimmunisation after Rh (D) positive platelet transfusions in patients undergoing haematopoietic stem cell transplantation

Solves P; (...); Sanz MA

Letter. 10.1111/tme.12179. 2015

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Ribera, Josep-Maria; (...); Sancho, Juan-Manuel

Meeting Abstract. 10.1182/blood-2019-125683. 2019

RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib

Such, E; (...); Cervera, J

Article. 10.1159/000497348. 2019

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Ribera, Jordi; (...); Ribera, Josep-Maria

Meeting Abstract. 10.1182/blood-2023-186265. 2023

Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia.

Review. 10.3389/fonc.2021.614215. 2021

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Paiva, B; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-113299. 2018

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.

Pinto-Merino, Alvaro; (...); Saiz-Rodriguez, Miriam

Article. 10.3390/pharmaceutics14030559. 2022

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2021-146503. 2021

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.

Montesinos P; (...); Wei AH

Article. 10.1038/s41375-020-0773-5. 2020

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

Review. 10.1007/s00277-018-3304-y. 2018

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups

Vives, Susana; (...); PETHEMA Grp

Article. 10.3390/cancers16234028. 2024

Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018

Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.

Moles-Poveda, P; (...); Botella-Estrada, R

Article. 10.1016/j.ad.2017.11.003. 2018

SCREENING FOR POTENTIAL THERAPEUTIC OPPORTUNITIES FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH IKZF1 DELETIONS

Ribera, Jordi; (...); Ribera, Josep Maria

Meeting Abstract. 2020

Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry

Espinoza, Marcela; (...); Martinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-185288. 2023

Secondary and Therapy-Related Acute Promyelocytic Leukemia. Experience of the PETHEMA Registry

Montesinos, P; (...); GATLA Cooperative Grp

Meeting Abstract. 2017

SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Paoli, Alessandro; (...); Pellacani, Andrea

Meeting Abstract. 10.1182/blood-2021-150277. 2021

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.

Cortes JE; (...); Heuser M

Review. 10.1080/10428194.2020.1817445. 2020

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

Aguas Peris M; (...); Nos, P

Article. 10.1097/MIB.0000000000001182. 2017

Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice

Aguas, M; (...); Nos, P

Meeting Abstract. 2017

Sex differences in aortic prognosis in Marfan patients, a retrospective longitudinal study from the REPAG registry

Tura, G. Teixido; (...); Cabrera, F.

Meeting Abstract. 10.1093/eurheartj/ehae666.2264. 2024

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Torrent, Anna; (...); Ribera, Josep-Maria

Meeting Abstract. 10.1182/blood-2024-207954. 2024

Single Nucleotide Polymorphisms, SNPs, Associated With the Efficacy and Security of Immunosuppressive Treatment in Heart Transplantation

Sanchez-Lazaro, I.; (...); Salvador-Sanz, A.

Article. 10.1016/j.healun.2014.01.392. 2014

Single umbilical cord blood with or without CD34(+) cells from a third-party donor in adults with leukemia.

Sanz, J; (...); Grp Espanol Trasplante

Article. 10.1182/bloodadvances.2017006999. 2017

Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia

Gómez-Seguí I; (...); Sanz MA

Article. 10.1371/journal.pone.0100245. 2014

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis.

Hernani, Rafael; (...); Solano, Carlos

Article. 10.1002/jha2.183. 2021

Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia

Weinhauser, I; (...); Rego, EM

Meeting Abstract. 10.1182/blood-2018-99-115370. 2018

SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022

SNPs and taxane toxicity in breast cancer patients

Bosó V; (...); Aliño SF

Article. 10.2217/PGS.14.127. 2014

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.

Risueno, Alberto; (...); Hasan, Maroof

Article. 10.1016/j.leukres.2024.107497. 2024

Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

Cantón R; (...); Solé A

Article. 10.1016/j.arbres.2014.09.021. 2015

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Zeidan, AM; (...); Mascarenhas, J

Review. 10.1016/S2352-3026(20)30205-2. 2020

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Shallis RM; (...); Zeidan AM

Article. 10.1016/S2352-3026(23)00159-X. 2023

STUDY OF CHRONIC ANEMIA IN THE ELDERLY

Villalba, A.; (...); Sanz, M. A.

Meeting Abstract. 2017

STUDY OF MUTATIONAL PROFILE AND CORRELATION OF RESPONSE TO EX VIVO PHARMACOLOGICAL TEST, IN THE DIAGNOSTIC OF THE AML

de la Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY

Ibanez, M; (...); Sanz, G

Meeting Abstract. 2017

STUDY OF THE CELL POPULATIONS INFUSED IN THE TRANSPLANT ALOGENICO OF BROTHER HLA-IDENTICAL

Villalba, A.; (...); Sanz, M. A.

Meeting Abstract. 2017

STUDY OF THE EFFECTIVENESS OF IMATINIB IN CHRONIC GRAFT-VERSUS-HOST DISEASE IN A SERIES OF 19 CASES

Poveda, PM; (...); Caballer, JS

Meeting Abstract. 2017

Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia

Dolz S; (...); Barragán E

Article. 10.3109/10428194.2015.1049167. 2016

STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS

Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente

Meeting Abstract. 2020

Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital

Pérez-Cebrián M; (...); Llopis-González A

Article. 2015

Summer Pruning, an Eco-Friendly Approach to Controlling Bitter Pit and Preserving Sensory Quality in Highly Vigorous Apple cv. 'Reinette du Canada'

Guerra, Marcos; (...); Antonio Casquero, Pedro

Article. 10.3390/agriculture11111081. 2021

Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia

Melo, CLS; (...); Montesinos, P

Meeting Abstract. 2021

Survival of Patients with Acute Myeloid Leukemia, Taken to Hematopoietic Stem Cell Transplantation: Experience of A Center in Colombia

Melo, CLS; (...); Ortiz, MF

Meeting Abstract. 2021

Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia

Ortiz, MF; (...); Sossa, C

Meeting Abstract. 2021

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Cortes, JE; (...); Heuser, M

Article. 10.1186/s13045-020-00929-8. 2020

Survival Outcomes for Patients (pts) in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine (Oral-AZA) or Placebo (PBO)

Pfeilstoecker, M.; (...); Doehner, H.

Meeting Abstract. 2023

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Ravandi, Farhad; (...); Doehner, Hartmut

Meeting Abstract. 10.1182/blood-2022-159045. 2022

Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)

Pfeilstoecker, Michael; (...); Menezes, Daniel

Meeting Abstract. 2022

Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.

Ravandi, Farhad; (...); Roboz, Gail J

Article. 10.1111/bjh.19202. 2023

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial.

Wei AH; (...); Ravandi F

Article. 10.3324/haematol.2022.282296. 2023

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Review. 10.3390/pharmaceutics14040878. 2022

T Cell-Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor Umbilical Cord Blood Transplantation

Moscardó F; (...); Sanz GF

Article. 10.1016/j.bbmt.2014.03.024. 2014

t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

Ribera, J; (...); Ribera, JM

Meeting Abstract. 2021

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

Sanford D; (...); Cortes JE

Article. 10.1111/bjh.13607. 2015

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Martín-Sánchez E; (...); Zabaleta A

Article. 10.1182/bloodadvances.2024013212. 2024

T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.

Chorao, Pedro; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2023.01.016. 2023

T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis

Gorin NC; (...); Acute Leukemia Working Party of the European Society for Blood and Marrow Transp

Article. 10.3324/haematol.2014.111450. 2015

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

Pigneux, A; (...); Bruggemann, M

Article. 10.1186/s12885-018-5002-5. 2018

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)

Montesinos, P; (...); Delgado, J

Letter. 10.1038/bmt.2016.145. 2016

The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022

The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation.

Piñana J; (...); Sanz J

Article. 10.1016/j.jinf.2019.12.022. 2020

THE COMBINATION OF GENOMIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IMPROVES THE STRATIFICATION OF ADULT PATIENTS WITH TYPE T-LYMPHOBLASTIC LEUKEMIA (LAL-T) TREATED ACCORDING TO THE PETHEMA PROTOCOLS

Gonzalez Gil, C.; (...); Genesca Ferrer, E.

Meeting Abstract. 2021

The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022

The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey.

Piñana JL; (...); Navarro D

Article. 10.1038/s41409-019-0698-7. 2020

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia

Lange, AP; (...); Rego, EM

Letter. 10.1111/bjh.14490. 2018

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

Platzbecker, Uwe; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-145099. 2021

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180482. 2023

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Rubio MT; (...); Mohty M

Article. 10.3324/haematol.2014.119339. 2015

The Interaction Between Collagen-Activated Platelets and Erythrocytes Selectively Increases the Release of Subsets of Platelet alpha-Granules Containing Pro-Angiogenic Substances

Teresa Santos, Maria; (...); Valles, Juana

Meeting Abstract. 2014

The Maternal Cytokine and Chemokine Profile of Naturally Conceived Gestations Is Mainly Preserved during In Vitro Fertilization and Egg Donation Pregnancies

Martínez-Varea A; (...); Pellicer A

Article. 10.1155/2015/128616. 2015

The modular network structure of the mutational landscape of Acute Myeloid Leukemia

Ibanez, M; (...); Cervera, J

Article. 10.1371/journal.pone.0202926. 2018

THE MODULAR NETWORK STRUCTURE OF THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA

Ibanez, M.; (...); Cervera, J.

Article. 2015

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Ayala, R; (...); Montesinos, P

Article. 10.3390/cancers13102458. 2021

The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations

Ibáñez, M; (...); Cervera, J.

Article. 10.1371/journal.pone.0148346. 2016

The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients

Ribera, J; (...); Ribera, JM

Article. 10.1111/bjh.15887. 2019

The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of oral CC-486 in patients with Acute Myeloid Leukemia (AML) in first remission

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.

Villar, Sara; (...); Montesinos, Pau

Article. 10.3389/fonc.2022.1054458. 2022

The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024

The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018

Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain

Boluda, B; (...); Montesinos, P

Article. 10.1007/s41669-018-0098-8. 2019

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.

Jonas, Brian A.; (...); Ofran, Yishai

Article. 10.1002/ajh.26600. 2022

Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020

Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.

Mora E; (...); Sanz J

Article. 10.1038/s41409-024-02298-z. 2024

Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020

Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024

Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.

Megías Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.rx.2015.01.008. 2015

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Patricia Simoes, Catia; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2022-163159. 2022

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.

Simoes, Catia; (...); Montesinos, Pau

Letter. 10.1111/bjh.18815. 2023

TRANSCRIPTIONAL CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA AT DIAGNOSIS IN THE ELDERLY PATIENT WITH IDENTIFICATION OF NEW PROGNOSTIC GROUPS

Sara, Villar; (...); Pau, Montesinos

Meeting Abstract. 2021

TRANSCRIPTOMICAL ANALYSIS AND MODELING IN C.ELEGANS OF THE IDH2 R140 R172 MUTATION

Gonzalez-Romero, E.; (...); Cervera-Zamora, J., V

Meeting Abstract. 2019

Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.

Solves, Pilar; (...); Sanz, Jaime

Article. 10.3390/jcm12103467. 2023

Transfusion Management and Immunohematologic Complications in Liver Transplantation: Experience of a Single Institution

Solves P; (...); Sanz MÁ

Article. 10.1159/000370260. 2015

Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation

Solves P; (...); Sanz MA

Article. 10.2450/2015.0195-14. 2015

TRANSFUSIONAL REQUIREMENTS OF PATIENTS UNDERGOING TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS OF DIFFERENT SOURCES

Blanco, JA; (...); Alonso, MAS

Meeting Abstract. 2018

Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

Lizan, L; (...); Polanco, C

Review. 10.2147/PPA.S67253. 2014

Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.

Klepin HD; (...); Cordoba R

Review. 10.1016/j.jgo.2020.03.019. 2020

Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

Ribera, JM; (...); Spanish Soc Hematology

Article. 10.1016/j.clml.2020.03.011. 2020

Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

Ribera JM; (...); Feliu E

Article. 10.1200/JCO.2013.52.2425. 2014

Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment

Montesinos P; (...); Sanz MÁ

Article. 10.1016/j.riam.2014.10.003. 2015

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-189800. 2023

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.

Lloret-Madrid, Pilar; (...); Montesinos, Pau

Article. 10.1002/cncr.35696. 2025

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1182/bloodadvances.2021005335. 2022

Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?